Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index; 5 of the 13 sources its claims cite were checked for support.
Abstract
A library of drugs that are in clinical trials or use was screened for inhibitors of hypoxia-inducible factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by >88% at a concentration of 0.4 microM. Eleven of these drugs were cardiac glycosides, including digoxin, ouabain, and proscillaridin A, which inhibited HIF-1alpha protein synthesis and expression of HIF-1 target genes in cancer cells. Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week. Enforced expression of HIF-1alpha by transfection was not inhibited by digoxin, and xenografts derived from these cells were resistant to the anti-tumor effects of digoxin, demonstrating that HIF-1 is a critical target of digoxin for cancer therapy.
Overview
CoChat Summary
TL;DR
A screen of 3,120 clinically used or trial drugs identified cardiac glycosides, including digoxin, as potent inhibitors of HIF-1α protein synthesis. Digoxin blocked HIF-1 target gene expression and inhibited tumor xenograft growth, with resistance in cells expressing HIF-1α from a transfected vector lacking HIF-1α mRNA untranslated regions.
Key findings
- In a Hep3B-c1 reporter screen, 336 of 3,120 drugs reduced hypoxia-induced firefly/Renilla luciferase activity by ≥50% at 10 µM; after re-screening, the top 20 drugs caused ≥88% inhibition at 0.4 µM, and 11 of these 20 were cardiac glycosides, including digoxin, ouabain, and proscillaridin A.
- Cardiac glycosides inhibited hypoxia-induced HIF-1α and HIF-2α protein expression at concentrations ≥50 nM and decreased mRNA levels of HIF-1 target genes HK1, HK2, and GLUT1 at 1% O2, without inhibiting HIF-1α mRNA.
- Digoxin inhibited HIF-1α protein synthesis independently of the PHD-VHL-proteasome pathway, mTOR/RPS6, Na+/K+ ATPase α1, and topoisomerases; pulse-labeling showed digoxin reduced de novo HIF-1α synthesis by 73% while overall protein synthesis was inhibited by only 19%.
- In SCID mouse xenografts, daily i.p. digoxin at 0.5 or 2 mg/kg inhibited P493-Myc tumor growth dose-dependently; 2 mg/kg inhibited PC3 tumor growth, and delayed treatment of established tumors (mean volume 100 mm3) caused growth arrest within 7 days. PC3-CA5 xenografts expressing constitutively active HIF-1α were resistant to digoxin’s anti-tumor effect.
Methods
- Cell-based screen using Hep3B-c1 cells stably transfected with an HRE-driven firefly luciferase reporter and a constitutive Renilla luciferase reporter; the Hopkins Drug Library of 3,120 FDA-approved or phase II drugs was screened at 10 µM, then re-screened at 2 µM and 0.4 µM.
- Mechanistic assays included immunoblotting for HIF-1α/HIF-2α, quantitative real-time RT-PCR for HIF-1 target mRNAs, [35S]methionine/cysteine pulse-labeling with HIF-1α immunoprecipitation, shRNA knockdown of Na+/K+ ATPase α1 and topoisomerases, flow cytometry, and annexin V staining.
- In vivo studies used SCID mice bearing P493-Myc, PC3-EV, or PC3-CA5 xenografts; digoxin was administered by daily intraperitoneal injection, with tumor volume, body weight, tumor HIF-1α protein, and HIF-1 target gene mRNAs assessed.
Limitations
- The paper states that digoxin has both HIF-1α-dependent and HIF-1α-independent effects on cell growth, based on PC3-CA5 cells growing similarly to vehicle-treated PC3-EV cells.
- Evident from the text: the mechanistic and in vivo work relies on specific cell lines and SCID mouse xenograft models, with no human clinical outcomes reported.
- The provided text is truncated before the end of the Discussion, so any additional limitations stated there are not available.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 4 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIF-1 also controls the expression of genes involved in tumor cell immor- talization, stem cell maintenance/de-differentiation, genetic in- stability, autocrine growth, invasion/metastasis, and treatment failure (6, 7).”
What the sources say
- Not checked — no full text of the sourcecites [6] matched to “Evaluation of HIF-1 inhibitors as anticancer agents” (2007) source
- Partly supportedcites [7] matched to “The role of hypoxia-inducible factors in tumorigenesis” (2008) sourceExperimental — accuracy not yet measured
The Figure 3 caption (Angiogenesis section; page not provided) says HIF-regulated genes contribute to proliferation, invasion, and metastasis, and the Differentiation discussion links HIF signaling to an undifferentiated state. But the review does not establish that HIF-1 controls genes for every listed outcome: it attributes direct Oct4 regulation to HIF-2, does not substantiate immortalization or genetic instability, and describes HIF-1’s effects on radiotherapy response as mixed rather than simply causing treatment failure. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Digitoxin inhibited the development of skin pap- illomas in mice treated with dimethylbenzanthracene and tetra- decanoylphorbol ester (34).”
What the sources say
- Supportedcites [34] matched to “Anti-tumor Promoting Activities of Natural Products. II. Inhibitory Effects of Digitoxin on Two-Stage Carcinogenesis of Mouse Skin Tumors and Mouse Pulmonary Tumors.” (1993) source
The Results and Discussion (p. 1) report that digitoxin delayed skin papilloma formation and reduced both the proportion of mice bearing papillomas and the average number per mouse. The figure caption on the same page identifies DMBA as the initiator and TPA as the promoter. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The growth of digoxin-treated PC3-CA5 cells was similar to that of vehicle-treated PC3-EV cells.”
§ 4 h pretreatment > 1.00 0.31 0.270.12
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When Hep3B-c1 cells were cultured under hypoxic conditions (1% O2), the ratio of firefly/Renilla luciferase activity was ten-fold higher than when the cells were cultured under nonhy- poxic conditions (20% O2) for 24 h (Fig. 1B).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were obtained in Hep3B cells treated with 100 nM digoxin (Fig. 1G).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 27 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, pharmacologic depletion of HIF1α by small molecules PX478 and Digoxin41,42 also produced similar results in T and NK cells (Fig. 4g, h and Fig. S5f, g, h).”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Digoxin, which is currently passing phase I clinical trials, was reported to inhibit established tumor xenografts with no effect on the growth of constitutively expressing HIF-1 xenografts.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vivo, digoxin inhibits tumor growth and suppresses lung metastasis in orthotopic breast cancer models [295,297].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In HepB cells, these agents reduced both HIF-1α and HIF-2α protein levels without altering HIF1A mRNA, indicating post-transcriptional regulation [295].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredIn the citing paper
“One significant hurdle for the use of these compounds, however, is the lack of specificity of these compounds for specific blockade of HIF (such as digoxin, acriflavine, and 17-AAG) identified to date [124–126].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [125]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · cited 1×
“HIF-1 is a heterodimeric protein that is composed of O2regulated HIF-1 and constitutively expressed HIF-1 subunits (8, 9).”
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“VHL loss-of-function results in constitutive expression of HIF-1 in the majority of clear cell renal carcinomas (11).”
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“Under normoxic conditions, HIF-1 is hydroxylated on proline residue 564 and/or 402 by proline hydroxylase domain protein 2 (PHD2), which is required for the binding of the von Hippel-Lindau protein (VHL), the recognition subunit of an E3 ubiquitin-protein ligase that targets HIF-1 for proteasomal degradation (10).”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
(1999) · PubMed · Cited by 2,204
Self-citationPurification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Self-citationRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Whereas VHL loss-of-function leading to dysregulated HIF-1 expression is restricted to renal cell carcinoma and cerebellar hemangioblastoma, many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Self-citationTalks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Cited by
Items 101–200 of 620
Lan, J., Lu, H., Samanta, D., Salman, S., Lu, Y., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809695115 · Cited by 127
“To complement these RNA interference studies, we took a pharmacologic approach by treating cells with digoxin or acriflavine, which inhibit HIF-1 activity in hypoxic cells by distinct molecular mechanisms: Digoxin blocks HIF-1α protein accumulation (35), whereas acriflavine blocks the dimerization of HIF-1α with HIF-1…”
Self-citationOgle, M. E., Gu, X., Espinera, A. R., & Wei, L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.020 · Cited by 144
“DIG inhibits HIF by inhibiting the protein translation frommRNA, and since the protein is rapidly turned over in normoxic conditions, the net effect is to reduce protein expression of HIF-1α (Zhang et al., 2008).”
InfluentialZhang, J., Yao, M., Xia, S., Zeng, F., & Liu, Q. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00682-7 · Cited by 126
The potential role of HIF on tumour progression and dissemination
Unwith, S., Zhao, H., Hennah, L., & Ma, D. (2014) · International Journal of Cancer · doi:10.1002/ijc.28889 · Cited by 134
Identification of a Novel Small Molecule HIF-1α Translation Inhibitor
Narita, T., Yin, S., Gelin, C. F., Moreno, C. S., Yepes, M., Nicolaou, K. C., & Van Meir, E. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3180 · Cited by 123
“Therefore, various small molecules targeting the HIF pathway have been developed (11,31–37).”
BackgroundDigitoxin and its analogs as novel cancer therapeutics
Elbaz, H. A., Stueckle, T. A., Tse, W. W., Rojanasakul, Y., & Dinu, C. Z. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-4 · Cited by 131
Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
Calderón‐Montaño, J. M., Burgos‐Morón, E., Orta, M. L., Maldonado-Navas, D., García-Domínguez, I., & López‐Lázaro, M. (2014) · BioMed Research International · doi:10.1155/2014/794930 · Cited by 137
Rey, S., Lee, K., Wang, C. J., Gupta, K., Chen, S., McMillan, A., Bhise, N., Levchenko, A., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911921106 · Cited by 120
“To determine whether the effect of DMOG was HIF-1-dependent, BMDACs were cultured in the presence of DMOG and digoxin, which inhibits HIF-1 and HIF-2 protein synthesis (31).”
MethodSelf-citationGlioblastoma, Cancer Stem Cells and Hypoxia
Bar, E. E. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00460.x · Cited by 137
Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis
Ouyang, X., Han, S.-N., Zhang, J.-Y., Dioletis, E., Nemeth, B. T., Pacher, P., Feng, D., Bataller, R., Cabezas, J., Stärkel, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.01.007 · Cited by 115
“These mechanistic insights into the role of the HIF-1a pathway in sterile inflammation may have great clinical relevance due to the ability of cardiac glycosides (CGs) to inhibit HIF-1a activation (Zhang et al., 2008).”
BackgroundTargeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy
Rey, S., Schito, L., Wouters, B. G., Eliasof, S. D., & Kerbel, R. S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.05.002 · Cited by 122
Self-citationSynthesis, biological function and evaluation of Shikonin in cancer therapy
Wang, F., Yao, X., Zhang, Y., & Tang, J. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.03.005 · Cited by 113
Wang, H., Zhang, C., Xu, L., Zang, K., Ning, Z., Jiang, F., Chi, H., Zhu, X., & Meng, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.7935 · Cited by 116
Digoxin inhibits retinal ischemia‐induced HIF‐1α expression and ocular neovascularization
Yoshida, T., Zhang, H., Iwase, T., Shen, J., Semenza, G. L., & Campochiaro, P. A. (2010) · The FASEB Journal · doi:10.1096/fj.09-145664 · Cited by 111
“For each primer pair, annealing temperature was optimized by gradient PCR and linearity of all assays was established by strict criteria (27).”
MethodSelf-citationEffect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer
Shim, J. S., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H.-E. C., Dhara, S., Han, K. C., Chong, C. R., Pomper, M. G., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq457 · Cited by 112
Self-citationSalman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111
Self-citationTerzuoli, E., Puppo, M., Rapisarda, A., Uranchimeg, B., Cao, L., Burger, A. M., Ziche, M., & Melillo, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1075 · Cited by 111
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy
Martínez‐Sáez, O., Borau, P. G., Alonso‐Gordoa, T., Molina‐Cerrillo, J., & Grande, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.013 · Cited by 116
“…cavity of HIF-2 and interfere with the heterodimerization lectivity Other targets F- 1 F-1 F-1 and HIF-2 Na+/K+ ATPase DNA topoisomerase I and II (Zhang et al., 2008; Winnicka et al., 2008) F-1 F-1 and HIF-2 Topoisomerase I Nuclear factor- B (NF- B) activation (Piret and Piette, 1996) F-1 and…”
BackgroundHypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells
Hajizadeh, F., Okoye, I., Esmaily, M., Chaleshtari, M. G., Masjedi, A., Azizi, G., Irandoust, M., Ghalamfarsa, G., & Jadidi‐Niaragh, F. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116952 · Cited by 112
Drug Repositioning for Effective Prostate Cancer Treatment
Turanlı, B., Grøtli, M., Borén, J., Nielsen, J., Uhlén, M., Arğa, K. Y., & Mardinoğlu, A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00500 · Cited by 126
“Despite the great potential of the activity-based DR, even the largest publicly available drug collection, JHCCL, covers almost 30% of roughly 10,000 drugs in clinic.”
InfluentialHypoxia-induced macropinocytosis represents a metabolic route for liver cancer
Zhang, M. S., Cui, J. D., Lee, D., Yuen, V. W., Chiu, D. K., Goh, C. C., Cheu, J. W., Tse, A. P., Bao, M. H., Wong, B. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28618-9 · Cited by 115
Wang, Y., Qiu, Q., Shen, J., Li, D.-D., Jiang, X., Si, S., Shao, R., & Wang, Z. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.06.028 · Cited by 112
Felth, J., Rickardson, L., Rosén, J., Wickström, M., Fryknäs, M., Lindskog, M., Bohlin, L., & Gullbo, J. (2009) · Journal of Natural Products · doi:10.1021/np900210m · Cited by 104
Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides
Cerella, C., Dicato, M. A., & Diederich, M. F. (2012) · Mitochondrion · doi:10.1016/j.mito.2012.06.003 · Cited by 109
Digoxin inhibits development of hypoxic pulmonary hypertension in mice
Abud, E. M., Maylor, J., Undem, C., Punjabi, A., Zaiman, A. L., Myers, A. C., Sylvester, J. T., Semenza, G. L., & Shimoda, L. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120385109 · Cited by 102
“One member of this class, digoxin, inhibited HIF-1α protein translation and blocked HIF-1 activity in vivo (15, 16).”
InfluentialSelf-citationTargeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy
Ma, Z., Wang, L. Z., Cheng, J.-T., Lam, S. T., Ma, X., Xiang, X., Wong, A. L., Goh, B. C., Gong, Q., Sethi, G., et al. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7935 · Cited by 107
“Silencing HIF-1 a or HIF-2 a in breast cancer cells inhibited lymph node metastasis in a mouse model (115).”
Xu, W., Zheng, H., Yang, R., Liu, T., Yu, W., Zheng, X., Li, B., Jiang, S., & Jiang, L. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0331-2 · Cited by 103
Zhang, J., Hu, Z., Horta, C. A., & Yang, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.002 · Cited by 113
Tafani, M., Pucci, B., Russo, A., Schito, L., Pellegrini, L., Perrone, G. A., Villanova, L., Salvatori, L., Ravenna, L., Petrangeli, E., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00013 · Cited by 99
“Digoxin has been used for treatment of heart disease for a long time and it is therefore of particular interest for a combinatorial therapy with other conventional anti-tumor agents (Zhang et al., 2008).”
BackgroundHypoxia: Friend or Foe for drug delivery in Pancreatic Cancer
Shah, V. M., Sheppard, B. C., Sears, R. C., & Alani, A. W. G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.041 · Cited by 119
Sarkar, K., Cai, Z. P., Gupta, R., Parajuli, N., Fox-Talbot, K., Darshan, M. S., Gonzalez, F. J., & Semenza, G. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208314109 · Cited by 105
“Digoxin inhibits the translation of HIF-1α mRNA into protein (36), whereas acriflavine binds to HIF-1α and inhibits dimerization with HIF-1β (37).”
BackgroundSelf-citationHu, Y., Yu, K., Wang, G., Zhang, D., Shi, C., Ding, Y., Hong, D., Zhang, D., He, H., Sun, L., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.023 · Cited by 98
Shan, L., Zhou, X., Liu, X., Wang, Y., Su, D., Hou, Y., Yu, N., Yang, C., Liu, B., Gao, J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.010 · Cited by 100
de Sousa, L. Q., Machado, K. D. C., Oliveira, S. F. D. C., Araújo, L. D. S., Filho, E. D. S. M., Cavalcante, A. A. D. C. M., Júnior, G. M. V., & Ferreira, P. M. P. (2017) · Toxicon · doi:10.1016/j.toxicon.2017.01.004 · Cited by 101
Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition
Wang, Z., Zheng, M., Li, Z. F., Li, R., Jia, L., Xiong, X., Southall, N. T., Wang, S., Xia, M., Austin, C. P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0891 · Cited by 105
“Digoxin or ouabain also remarkably inhibit protein synthesis of HIF-1a to block HIF1 transcription factor activity and to inhibit tumor cell growth both in vitro and in vivo (37).”
BackgroundHIF and pulmonary vascular responses to hypoxia
Shimoda, L. A., & Laurie, S. S. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00643.2013 · Cited by 95
Song, X., Chen, J., Zhao, M., Zhang, C., Yu, Y., Lonard, D. M., Chow, D., Palzkill, T. G., Xu, J., O’Malley, B. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604274113 · Cited by 100
“Oxygen Sensing” by Na,K-ATPase: These Miraculous Thiols
Bogdanova, A. Y., Petrushanko, I. Y., Hernansanz‐Agustín, P., & Martínez-Ruiz, A. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00314 · Cited by 111
“As PLM is a regulatory subunit that is shared between the Na,K-ATPase and the Na/Ca exchanger, it was suggested that Sglutathionylation as well as its redox-sensitive phosphorylation of it impacts activity of both transporters (Silverman et al., 2005; Cheung et al., 2007; Zhang et al., 2011).”
BackgroundPrassas, I., Karagiannis, G. S., Batruch, I., Dimitromanolakis, A., Datti, A., & Diamandis, E. P. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0421 · Cited by 94
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 99
Na+/K+-ATPase Revisited: On Its Mechanism of Action, Role in Cancer, and Activity Modulation
Bejček, J., Spiwok, V., Kmoníčková, E., & Rimpelová, S. (2021) · Molecules · doi:10.3390/molecules26071905 · Cited by 98
Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis
Wang, R., Godet, I., Yang, Y., Salman, S., Lu, H., Lyu, Y., Zuo, Q., Wang, Y., Zhu, Y., Chen, C. O., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020490118 · Cited by 103
Self-citationTsai, S., Huang, P., Hsu, Y., Peng, Y., Lee, C., Wang, J., Chen, J., & Lin, S. (2016) · Scientific Reports · doi:10.1038/srep28612 · Cited by 88
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
“Another mechanism of antitumor action has been proposed for ABZ; it inhibited vascular endothelial growth factor (VEGF) production and tumor angiogenesis in mice bearing peritoneal ovarian tumors (54).”
BackgroundInfluentialReddy, D., Kumavath, R., Barh, D., Azevedo, V., & Ghosh, P. (2020) · Molecules · doi:10.3390/molecules25163596 · Cited by 106
Targeting hypoxic response for cancer therapy
Paolicchi, E., Gemignani, F., Krstic-Demonacos, M., Dedhar, S., Mutti, L., & Landi, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7229 · Cited by 88
“Digoxin, a cardiac glycoside, it has been shown to have anti-cancer activity due to the inhibition of HIF1A synthesis, in vitro and in vivo in several solid tumors [76-78].”
Vascular disrupting agents in cancer therapy
Smolarczyk, R., Czapla, J., Jarosz–Biej, M., Czerwinski, K., & Cichoń, T. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173692 · Cited by 92
Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation
Abu‐Remaileh, M., & Aqeilan, R. I. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.95 · Cited by 91
Hypoxia-inducible factor-1α: A promising therapeutic target for vasculopathy in diabetic retinopathy
Li, H.-Y., Yuan, Y., Fu, Y.-H., Wang, Y., & Gao, X.-Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104924 · Cited by 88
Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery
Li, H., Zhou, H., Wang, D., Qiu, J., Zhou, Y., Li, X., Rosenfeld, M. G., Ding, S., & Fu, X.-D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200305109 · Cited by 86
Spirig, R., Djafarzadeh, S., Regueira, T., Shaw, S. G., von Garnier, C., Takala, J., Jakob, S. M., Rieben, R., & Lepper, P. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010983 · Cited by 85
Systems biology of oxygen homeostasis
Samanta, D., Prabhakar, N. R., & Semenza, G. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1382 · Cited by 85
Self-citationCardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis
Perne, A., Muellner, M. K., Steinrueck, M., Craig-Mueller, N., Mayerhofer, J., Schwarzinger, I., Sloane, M., Uras, I. Z., Hoermann, G., Nijman, S. M. B., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008292 · Cited by 83
“CGs show in vitro activity against a broad range of cell types and a number of compound screens have recently rediscovered that CGs inhibit proliferation in various assays [2,5,6,7].”
BackgroundMethodInfluentialChanging the energy of an immune response.
Delmastro-Greenwood, M. M., & Piganelli, J. D. (2013) · Europe PMC (PubMed Central) · Cited by 106
Cancer stem cells: a new framework for the design of tumor therapies
Garvalov, B. K., & Acker, T. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0685-3 · Cited by 99
Rogers, J. T., Mikkilineni, S., Cantuti‐Castelvetri, I., Smith, D. H., Huang, X., Bandyopadhyay, S., Cahill, C. M., Maccecchini, M. L., Lahiri, D. K., & Greig, N. H. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0513-5 · Cited by 84
Sharma, A., Sinha, S., & Shrivastava, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.849040 · Cited by 93
“Digoxin (DIG) (PubChem CID: 2724385), a cardiac glycoside, has been demonstrated to have an anti-cancer effect in vitro and in vivo in various solid tumors by inhibiting HIF-1α production (Newman et al., 2008; Zhang et al., 2008; Lin et al., 2009).”
BackgroundZhou, Y., Zhou, Y., Yang, M., Wang, K., Liu, Y., Mingda, Z., Yang, Y., Jin, C.-Y., Wang, R., & Hu, R. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101131 · Cited by 83
Hattori, H., Okuda, K., Murase, T., Shigetsura, Y., Narise, K., Semenza, G. L., & Nagasawa, H. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.060 · Cited by 82
Self-citationHypoxia‐inducible factor‐1 as a therapeutic target in cancer
Tang, C., & Yu, J. Q. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12038 · Cited by 84
Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F. A., Pili, R., & Rustum, Y. M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-293 · Cited by 79
“ment of agents that would effectively inhibit HIF-1α synthesis [50-52].”
BackgroundSilva, V. L., & Al-Jamal, W. T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.013 · Cited by 78
The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer
Yong, L., Tang, S., Yu, H., Zhang, H., Zhang, Y., Wan, Y., & Cai, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964934 · Cited by 91
“In a study, Hep3B cells were exposed to vector (-) and 100 nM digoxin (+) under hypoxia, followed by a western blot analysis, displaying a significant decrease in HIF-1a protein levels in the digoxin exposed group (105).”
MethodSelf-citationYuan, G., Peng, Y.-J., Reddy, V. D., Makarenko, V. V., Nanduri, J., Khan, S. A., Garcia, J. A., Kumar, G. K., Semenza, G. L., & Prabhakar, N. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305961110 · Cited by 77
“Digoxin is a potent inhibitor of HIF-1α protein expression (20) and Hif2α mice treated with digoxin (1 mg per kg per d i.”
BackgroundSelf-citationRetractedVeith, C., SCHERMULY, R. T., Brandes, R. P., & Weißmann, N. (2015) · The Journal of Physiology · doi:10.1113/jp270689 · Cited by 79
“In this regard cardiac glycosides, such as digoxin, ouabain or proscillaridin A, inhibit HIF protein synthesis and HIF target gene expression (Zhang et al. 2008; Yoshida et al. 2010).”
BackgroundTargeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor
Nordgren, I. K., & Tavassoli, A. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15032d · Cited by 76
Sustained delivery of a HIF-1 antagonist for ocular neovascularization
Iwase, T., Fu, J., Yoshida, T., Muramatsu, D., Miki, A., Hashida, N., Lu, L., Oveson, B., Lima e Silva, R., Seidel, C., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.008 · Cited by 75
“This screen identified digoxin and other cardiac glycosides and the anthracycline chemotherapeutic agents doxorubicin (DXR) and daunorubicin (DNR) as potent inhibitors of HIF-1-mediated gene transcription (19,20).”
BackgroundSelf-citationEmergence of Cardiac Glycosides as Potential Drugs: Current and Future Scope for Cancer Therapeutics
Kumavath, R., Paul, S., Pavithran, H., Paul, M. K., Ghosh, P., Barh, D., & Azevedo, V. (2021) · Biomolecules · doi:10.3390/biom11091275 · Cited by 101
“Following the initial findings, a comprehensive screening of drugs as inhibitors of (HIF1) through clinical trials found that CGs, including digitoxin could inhibit HIF-1 and downstream genes in the process of transcription [45].”
BackgroundRanasinghe, W. K. B., Xiao, L., Kovac, S., Chang, M., Michiels, C., Bolton, D., Shulkes, A., Baldwin, G. S., & Patel, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054251 · Cited by 76
Huang, L. F., Injac, S. G., Cui, K., Braun, F., Qi, L., Du, Y., Zhang, H., Kogiso, M., Lindsay, H., Zhao, S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0150 · Cited by 77
“Other mechanisms that have been suggested for the effects of cardiac glycosides on various classes of tumor cells include the inhibition of hypoxia signaling (26, 44), global suppression of protein synthesis (45), modulation of EGFR/ERK/AKT signaling (40), and disruption of mitochondrial function via calcium-based sig…”
Self-citationHypoxia-inducible factors enhance glutamate signaling in cancer cells
Hu, H., Takano, N., Xiang, L., Gilkes, D. M., Luo, W., & Semenza, G. L. (2014) · Oncotarget · doi:10.18632/oncotarget.2593 · Cited by 75
“Previously studies have demonstrated that administration of the HIF-1 inhibitor digoxin also significantly inhibits Hep3B tumor xenograft growth (Zhang et al., 2008) and HIF inhibitor also impairs ccRCC tumor growth (Chintala et al.”
Self-citationKhatri, H. R., Bhattarai, B. T., Kaplan, W., Zhong-zheng, L., Long, M. J. C., Aye, Y., & Nagorny, P. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b12870 · Cited by 77
Yang, H., Geng, Y., Wang, P., Zhou, Y., Yang, H., Huo, Y., Zhang, H., Li, Y., He, H., Tian, X., et al. (2019) · Cancer Science · doi:10.1111/cas.14086 · Cited by 74
Self-citationZhang, Q., Doucet, M., Tomlinson, R. E., Han, X., Quarles, L. D., Collins, M. T., & Clemens, T. L. (2016) · Bone Research · doi:10.1038/boneres.2016.11 · Cited by 75
An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
Shirai, Y., Chow, C. C. T., Kambe, G., Suwa, T., Kobayashi, M., Takahashi, I., Harada, H., & Nam, J. (2021) · Cancers · doi:10.3390/cancers13112813 · Cited by 79
The Inflammasome in Liver Injury and Non-Alcoholic Fatty Liver Disease
Mehal, W. Z. (2014) · Digestive Diseases · doi:10.1159/000360495 · Cited by 83
Blaustein, M. P., & Hamlyn, J. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.02.011 · Cited by 72
Hypoxia and cancer cell metabolism
Huang, D., Li, C., & Zhang, H. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt148 · Cited by 84
Self-citationJham, B. C., Ma, T., Hu, J., Chaisuparat, R., Friedman, E. R., Pandolfi, P. P., Schneider, A., Sodhi, A., & Montaner, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019103 · Cited by 76
“for 10 consecutive days [31].”
Targeting Ion Channels for Cancer Treatment: Current Progress and Future Challenges
Capatina, A. L., Lagos, D., & Brackenbury, W. J. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_46 · Cited by 86
López-Codony, V., & Tavassoli, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101017 · Cited by 77
Zhao, W., Li, A., Feng, X., Hou, T., Liu, K., Liu, B., & Zhang, N. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.06.018 · Cited by 69
Chintala, S., Tόth, K., Cao, S., Durrani, F. A., Vaughan, M. M., Jensen, R. L., & Rustum, Y. M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1238-8 · Cited by 68
“Among these 20 inhibitors, digoxin and other cardiac glycosides [32] as well as the anthracycline chemotherapeutic agents doxorubicin, daunorubicin [33] were identified as inhibitors of HIF-1α and demonstrated that HIF-1α inhibition resulted in growth inhibition of tumor.”
Rey, S., Luo, W., Shimoda, L. A., & Semenza, G. L. (2011) · Blood · doi:10.1182/blood-2010-11-321190 · Cited by 68
Self-citationDong, A., Seidel, C. P., Snell, D. C., Ekawardhani, S., Ahlskog, J., Baumann, M. J., Shen, J., Iwase, T., Tian, J., Stevens, R., et al. (2013) · Angiogenesis · doi:10.1007/s10456-013-9402-5 · Cited by 74
“This was also suggested by the strong suppression of subretinal NV by digoxin [9], which blocks HIF-1 transcriptional activation [10].”
Schaible, E., Windschügl, J., Bobkiewicz, W., Kaburov, Y., Dangel, L., Krämer, T. J., Huang, C., Sebastiani, A., Luh, C., Werner, C. D., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12708 · Cited by 75
“Among the identified substances are those inhibiting HIF-1a such as the cardiac glycoside digoxin (Zhang et al. 2008) or the estrogen metabolite 2-Methoxyestradiol (2ME2) (Mooberry 2003) and, on the other hand, prolyl-hydroxylase inhibitors such as dimethyloxalylglycine which stabilize and thus stimulate HIF-1a functi…”
BackgroundParoni, R. C., Terraneo, L., Bonomini, F., Finati, E., Virgili, E., Bianciardi, P., Favero, G., FRASCHINI, F., Reiter, R. J., Rezzani, R., et al. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12142 · Cited by 73
“digoxin, has been used for decades in the treatment of prostate cancer [50], another inhibitor, topotecan, failed to show significant anticancer effects in clinical trials.”
BackgroundLópez‐Lázaro, M. (2015) · Oncoscience · doi:10.18632/oncoscience.132 · Cited by 80
“It is therefore relatively easy to find a marked in vivo anticancer activity if one transplants human cancer cells into mice and then treats the animals with a cardiac glycoside such as bufalin or proscillaridin A [4,10,13-16].”
BackgroundHypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease
Wang, W., Xu, B., Xuan, H., Ge, Y., Wang, Y., Wang, L., Huang, J., Fu, W., Michie, S. A., & Dalman, R. L. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.09.030 · Cited by 72
“Dosages were selected on the basis of those proven effective in prior published studies in other disease mouse models.(31,32) To evaluate the effect of HIF-1a”
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
Li, R.-Z., Fan, X., Duan, F., Jiang, Z., Pan, H., Luo, L., Zhou, Y., Li, Y., Yao, Y., Yao, X., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0733-4 · Cited by 65
Wang, Y., Ma, Q., Zhang, S., Liu, H., Zhao, B., Du, B., Wang, W., Lin, P., Zhang, Z., Zhong, Y., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00186 · Cited by 77
“, 2016), as well as inhibition of HIF-1a synthesis (Zhang et al., 2008; Gayed et al., 2012) were reported to play roles in the anticancer effects of digoxin.”
BackgroundZEB1 Promotes Invasion in Human Fetal Neural Stem Cells and Hypoxic Glioma Neurospheres
Kahlert, U. D., Suwala, A. K., Raabe, E. H., Siebzehnrübl, F. A., Suarez, M. J., Orr, B. A., Bar, E. E., Maciaczyk, J., & Eberhart, C. G. (2014) · Brain Pathology · doi:10.1111/bpa.12240 · Cited by 67
“The cardiac glycoside digoxin has been shown to lower HIF1α levels in cancer (60), including glioma neurospheres (3).”
BackgroundWang, L., Chen, G., Lu, X., Wang, S., Han, S., Li, Y., Ping, G., Jiang, X., Li, H., Yang, J., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.036 · Cited by 64
Hypoxia-inducible factor-1alpha in hepatic fibrosis: A promising therapeutic target
Zhan, L., Huang, C., Meng, X., Song, Y., Wu, X. Q., Yang, Y., & Li, J. (2014) · Biochimie · doi:10.1016/j.biochi.2014.10.013 · Cited by 63
Hypoxia Promotes Uveal Melanoma Invasion through Enhanced Notch and MAPK Activation
Asnaghi, L., Lin, M. H., Lim, K. S., Lim, K. J., Tripathy, A., Rodrigues, M. W., Merbs, S. L., Handa, J. T., Sodhi, A., Bar, E. E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105372 · Cited by 74
“Since digoxin, a cardiac glycoside used in the treatment of atrial fibrillation and heart failure, is also known to inhibit HIF-1a protein synthesis [41], we used this compound to pharmacologically suppress HIF-1a and analyze the effects on growth and invasion in uveal melanoma lines.”
BackgroundSynergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma
Eskiocak, U., Ramesh, V., Gill, J. G., Zhao, Z., Yuan, S. W., Wang, M., Vandergriff, T., Shackleton, M., Quintana, E., Frankel, A. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms12336 · Cited by 63
Control of the Antitumor Immune Response by Cancer Metabolism
Domblides, C., Lartigue, L., & Faustin, B. (2019) · Cells · doi:10.3390/cells8020104 · Cited by 68
“Cardiac glycosides are also molecules that can inhibit HIF-1α, of which digoxin is one [219].”
Common cardiovascular medications in cancer therapeutics
Vaklavas, C., Chatzizisis, Y. S., & Tsimberidou, A. M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.009 · Cited by 68
Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control
Cheng, X., Prange-Barczynska, M., Fielding, J. W., Zhang, M., Burrell, A. L., Lima, J. D. C. C., Eckardt, L., Argles, I. L. A., Pugh, C. W., Buckler, K. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133194 · Cited by 62
“As disturbances of oxygen homeostasis are critical to many aspects of human disease, there is great interest in developing agents that modulate HIF pathways, and in defining the benefits and risks of their therapeutic use (4, 5).”
Background
Metadata
- Authors
- Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., & Semenza, G. L.
- Affiliations
- Johns Hopkins University (US)
- Department of Oncology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-12-16
- Volume
- 105
- Issue
- 50
- Pages
- 19579-19586
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2604945
- OpenAlex
- W2135664375
- Semantic Scholar
- ad3fa6ccad907da0a52a0b821d2be70006a9b6fd
- Cited by
- 624
- References
- 40
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 23 · 2023: 24 · 2022: 35 · 2021: 39 · 2020: 38 · 2019: 34 · 2018: 34 · 2017: 50 · 2016: 42 · 2015: 37 · 2014: 52 · 2013: 57 · 2012: 38
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Flight Attendant Medical Research Institute
- Johns Hopkins University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- digoxin, cardiac glycosides, HIF-1α, HIF-1, tumor growth inhibition, drug screening, ouabain, proscillaridin A, tumor xenografts, cancer therapy
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Cardiac Glycosides, Digoxin, Humans, Transcription, Genetic, Transfection, Protein Biosynthesis, Mice, SCID, Genes, Reporter, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Luciferases, Firefly, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.